Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Convertible Debt: 2019-2023

Historic Convertible Debt for Ocular Therapeutix (OCUL) over the last 5 years, with Dec 2023 value amounting to $9.1 million.

  • Ocular Therapeutix's Convertible Debt fell 68.21% to $9.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $9.1 million, marking a year-over-year decrease of 68.21%. This contributed to the annual value of $9.1 million for FY2023, which is 68.21% down from last year.
  • As of Q4 2023, Ocular Therapeutix's Convertible Debt stood at $9.1 million, which was up 4.26% from $8.8 million recorded in Q3 2023.
  • Over the past 5 years, Ocular Therapeutix's Convertible Debt peaked at $30.0 million during Q2 2023, and registered a low of $8.8 million during Q3 2023.
  • In the last 3 years, Ocular Therapeutix's Convertible Debt had a median value of $26.7 million in 2021 and averaged $24.3 million.
  • In the last 5 years, Ocular Therapeutix's Convertible Debt increased by 10.27% in 2020 and then slumped by 68.87% in 2023.
  • Ocular Therapeutix's Convertible Debt (Quarterly) stood at $24.3 million in 2019, then increased by 0.01% to $24.3 million in 2020, then rose by 8.75% to $26.4 million in 2021, then increased by 8.75% to $28.7 million in 2022, then slumped by 68.21% to $9.1 million in 2023.
  • Its last three reported values are $9.1 million in Q4 2023, $8.8 million for Q3 2023, and $30.0 million during Q2 2023.